Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Renoprotective effects of angiotensin II receptor blockade in type 1 diabetic patients with diabetic nephropathy

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Recommendations from the EXTRIP workgroup on extracorporeal treatment for baclofen poisoning

    Research output: Contribution to journalReviewResearchpeer-review

  2. Biomarkers for early detection of kidney disease: a call for pathophysiological relevance

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Meta-analysis uncovers genome-wide significant variants for rapid kidney function decline

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Complement activation is a crucial driver of acute kidney injury in rhabdomyolysis

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Effects of Dapagliflozin in Patients With Kidney Disease, With and Without Heart Failure

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

BACKGROUND: Angiotensin I-converting enzyme (ACE) inhibitors reduce angiotensin II formation and induce bradykinin accumulation. Animal studies suggest that bradykinin may play a role for the effects of ACE inhibition on blood pressure and kidney function. Therefore, we compared the renal and hemodynamic effects of specific intervention in the renin-angiotensin system by blockade of the angiotensin II subtype-1 receptor to the effect of ACE inhibition.

METHODS: A randomized, double-blind, cross-over trial was performed in 16 type 1 diabetic patients (10 men), age 42 +/- 2 years (mean +/- SEM). The study consisted of five periods, each lasting two months. The patients received losartan 50 mg, losartan 100 mg, enalapril 10 mg, enalapril 20 mg, and placebo in random order. At the end of each period, albuminuria, 24-hour blood pressure, and glomerular filtration rate (GFR) were determined.

RESULTS: Both doses of losartan and enalapril reduced albuminuria (P < 0.05) and mean arterial blood pressure (MABP; P < 0.05), whereas GFR remained stable. Albuminuria was reduced by 33% (95% CI, 12 to 51) on losartan 50 mg, 44% (95% CI, 26 to 57) on losartan 100 mg, 45% (95% CI, 23 to 61) on enalapril 10 mg, and 59% (95% CI, 39 to 72) on enalapril 20 mg, and MABP fell by 9 +/- 2, 8 +/- 2, 6 +/- 3, and 11 +/- 3 mm Hg (mean +/- SEM), respectively. No significant differences were found between the effects of losartan 100 mg and enalapril 20 mg. HbA1C and sodium intake remained unchanged throughout the study, whereas a significant rise in serum potassium occurred during ACE inhibition.

CONCLUSION: The angiotensin II subtype 1 receptor antagonist, losartan, reduces albuminuria and MABP similar to the effect of ACE inhibition. These results indicate that the reduction in albuminuria and blood pressure during ACE inhibition is primarily caused by interference in the renin-angiotensin system. Our study suggest that losartan represents a valuable new drug in the treatment of hypertension and proteinuria in type 1 diabetic patients with diabetic nephropathy.

Original languageEnglish
JournalKidney International
Volume57
Issue number2
Pages (from-to)601-6
Number of pages6
ISSN0085-2538
DOIs
Publication statusPublished - Feb 2000

    Research areas

  • Adult, Angiotensin Receptor Antagonists, Angiotensin-Converting Enzyme Inhibitors, Antihypertensive Agents, Cross-Over Studies, Diabetes Mellitus, Type 1, Diabetic Nephropathies, Double-Blind Method, Enalapril, Female, Glomerular Filtration Rate, Humans, Hypertension, Renal, Losartan, Male, Proteinuria, Receptor, Angiotensin, Type 1, Receptor, Angiotensin, Type 2, Renin-Angiotensin System, Clinical Trial, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't

ID: 51534136